Shanghai Henlius Biotech, Inc. (2696.HK)

HKD 40.35

(3.59%)

EBITDA Summary of Shanghai Henlius Biotech, Inc.

Shanghai Henlius Biotech, Inc.'s latest annual EBITDA in 2023 was 911.33 Million CNY , up 446.19% from previous year.
Shanghai Henlius Biotech, Inc.'s latest quarterly EBITDA in 2024 Q2 was 293.17 Million CNY , down 0.0% from previous quarter.
Shanghai Henlius Biotech, Inc. reported an annual EBITDA of -310.61 Million CNY in 2022, up 53.99% from previous year.
Shanghai Henlius Biotech, Inc. reported an annual EBITDA of -671.74 Million CNY in 2021, up 17.51% from previous year.
Shanghai Henlius Biotech, Inc. reported a quarterly EBITDA of 293.17 Million CNY for 2024 Q2, down 0.0% from previous quarter.
Shanghai Henlius Biotech, Inc. reported a quarterly EBITDA of N/A for 2023 FY, up 446.19% from previous quarter.

Annual EBITDA Chart of Shanghai Henlius Biotech, Inc. (2023 - 2017)

Historical Annual EBITDA of Shanghai Henlius Biotech, Inc. (2023 - 2017)

Year	EBITDA	EBITDA Growth
2023	911.33 Million CNY	446.19%
2022	-310.61 Million CNY	53.99%
2021	-671.74 Million CNY	17.51%
2020	-814.06 Million CNY	-10.2%
2019	-744 Million CNY	-84.97%
2018	-399.35 Million CNY	-33.9%
2017	-298.25 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	293.17 Million CNY	-2.76%
2024 Q2	293.17 Million CNY	0.0%
2023 FY	- CNY	446.19%
2023 Q1	205.62 Million CNY	160.68%
2023 Q4	309.5 Million CNY	3.55%
2023 Q3	298.89 Million CNY	45.36%
2023 Q2	205.62 Million CNY	0.0%
2022 Q4	-338.84 Million CNY	-346.32%
2022 Q3	137.56 Million CNY	1484.91%
2022 Q2	-9.93 Million CNY	0.0%
2022 Q1	-9.93 Million CNY	91.55%
2022 FY	- CNY	53.99%
2021 Q3	-117.57 Million CNY	16.95%
2021 Q2	-141.57 Million CNY	0.0%
2021 Q1	-141.57 Million CNY	30.61%
2021 FY	- CNY	17.51%
2021 Q4	-117.57 Million CNY	0.0%
2020 FY	- CNY	-10.2%
2020 Q4	-204.01 Million CNY	0.0%
2020 Q2	-211.71 Million CNY	0.0%
2020 Q1	-211.71 Million CNY	11.28%
2020 Q3	-204.01 Million CNY	3.64%
2019 Q4	-238.62 Million CNY	0.0%
2019 Q2	-127.64 Million CNY	6.54%
2019 Q1	-136.58 Million CNY	0.01%
2019 FY	- CNY	-84.97%
2019 Q3	-238.62 Million CNY	-86.94%
2018 Q4	-136.6 Million CNY	0.0%
2018 FY	- CNY	-33.9%
2018 Q3	-136.6 Million CNY	-23.3%
2018 Q2	-110.78 Million CNY	-204.76%
2018 Q1	-36.35 Million CNY	0.0%
2017 FY	- CNY	0.0%

Peer EBITDA Comparison of Shanghai Henlius Biotech, Inc.

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	-898.897%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	-87.211%